Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Neoadjuvant terapi (Tx) for Merkelcellekarcinom med PD-1-hæmmeren Cemiplimab (NeoMatryx)

Neoadjuvant terapi (Tx) for Merkelcellekarcinom med PD-1-hæmmeren Cemiplimab - En randomiseret, dobbeltblindet, placebo-kontrolleret, ikke-komparativ fase II-studie

The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

135

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Tyskland, 69120
        • Rekruttering
        • Nationales Centrum für Tumorerkrankungen
        • Kontakt:
          • Jessica Hassel, Prof. Dr.
      • Mannheim, Baden-Wurttemberg, Tyskland, 68161
        • Rekruttering
        • Universitätsklinikum Mannheim
        • Kontakt:
          • Jochen Utikal, Prof. Dr.
      • Tübingen, Baden-Wurttemberg, Tyskland, 72076
        • Rekruttering
        • Universitätsklinikum Tübingen
        • Kontakt:
          • Ulrike Leiter-Stöppke, Prof. Dr.
    • Bavaria
      • Regensburg, Bavaria, Tyskland, 93053
        • Rekruttering
        • Universitätsklinikum Regensburg
        • Kontakt:
          • Sebastian Haferkamp, Prof. Dr.
      • Würzburg, Bavaria, Tyskland, 97080
        • Rekruttering
        • Universitätsklinikum Würzburg
        • Kontakt:
          • Anja Gieserich, Dr.
    • Free and Hanseatic City of Hamburg
      • Hamburg, Free and Hanseatic City of Hamburg, Tyskland, 20246
        • Rekruttering
        • Universitätsklinikum Hamburg-Eppendorf
        • Kontakt:
          • Christoffer Gebhardt, Prof. Dr.
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland, 60590
        • Rekruttering
        • Universitätsklinikum Frankfurt
        • Kontakt:
          • Bastian Schilling, Prof. Dr.
    • North Rhine-Westphalia
      • Bielefeld, North Rhine-Westphalia, Tyskland, 33647
        • Rekruttering
        • Klinikum Bielefeld
        • Kontakt:
          • Selma Ugurel, Prof. Dr.
      • Essen, North Rhine-Westphalia, Tyskland, 45147
        • Rekruttering
        • Universitätsklinikum Essen
        • Kontakt:
          • Dirk Schadendorf, Prof. Dr.
      • Minden, North Rhine-Westphalia, Tyskland, 32429
        • Ikke rekrutterer endnu
        • Johannes Wesling Klinikum Minden
        • Kontakt:
          • Ralf Gutzmer, Prof. Dr.
    • Rhineland-Palatinate
      • Mainz, Rhineland-Palatinate, Tyskland, 55131
        • Rekruttering
        • Universitätsmedizin Mainz
        • Kontakt:
          • Stefan Grabbe, Prof. Dr.
    • Thuringia
      • Erfurt, Thuringia, Tyskland, 99089
        • Rekruttering
        • Helios Klinikum Erfurt
        • Kontakt:
          • Rudolph Herbst, Prof. Dr.

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion criteria

  1. Patient has signed informed written consent.

  2. Patients is 18 years and older at time of signing of written informed consent

  3. Patient has diagnosis of Merkel cell carcinoma in clinical stage II, or in stage I with minimum diameter of 1 cm, with primary tumor already removed and a planned sentinel lymph nodes biopsy still pending.

  4. Patient has ECOG performance status 0-2.

  5. Patients has adequate laboratory parameters particularly for the blood count, renal and liver function parameters.

    1. Absolute number of neutrophils ≥ 1.5 x 109/L
    2. Platelets ≥ 75 x 109/L
    3. Hemoglobin ≥ 9 g/dL
    4. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with Gilbert´s Disease and total bilirubin up to 3x ULN may be eligible after approval from trial's medical expert)
    5. AST (SGOT) and ALT (SGPT) ≤ 3x ULN
    6. AP ≤ 2.5x ULN
    7. Serum creatinine ≤ 2x ULN or creatinine clearance ≥ 40 mL/min
  6. Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of Cemiplimab. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy.

  7. Patient must be willing to allow translational work-up of tissue samples (PT, sentinel lymph node biopsy).

Exclusion criteria

  1. Patient has prior sentinel lymph node removal for the current MCC.

  2. Patients received prior treatment with immunotherapy (such as PD-1/PD-L1 or CTL4) or any other systemic anti-tumor (MCC) therapy (incl. investigational therapies)

  3. Patient has active or a history of hematological neoplasms including chronic lymphocytic leukemia (CLL), irrespective if these require treatment or not.

  4. Patient had prior organ transplantation including allogenic stem-cell transplantation.

  5. Patient receives immunosuppressive concomitant medication, EXCEPT for the following:

    i. Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection).

    ii. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent.

    iii. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).

  6. Patient has known hypersensitivity to any component of the Cemiplimab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.

  7. Patient has active autoimmune or inflammatory disorders.

  8. Patient has history of interstitial lung disease.

  9. Patient has active infection requiring systemic therapy.

  10. Patient has Active infection requiring systemic therapy, including uncontrolled HIV, HBV and HCV infection or diagnosis of immunodeficiency.

    NOTE: Patients are eligible if:

    • Patients have controlled HIV infection with CD4 counts is > 350 cells/μL and viral load is undetectable [HIV RNA PCR]. Patients with controlled HIV infection must be monitored per local standards during the trial.
    • Patients positive for HBV surface antigen have controlled HBV infection receiving anti-viral therapy and with undetectable serum viral load [HBV DNA PCR]. Patients with controlled infection must undergo periodic monitoring of HBV DNA and p must remain on anti-viral therapy for at least 6 months after last dose of Cemiplimab.
    • Patients positive for HCV antibody have controlled HCV infection with undetectable viral load [HCV RNA PCR].
  11. Patent received vaccination with any live vaccine (e.g., intranasal flu vaccine) within 4 weeks before the first dose of Cemiplimab or planned vaccination with live vaccine during the trial

  12. Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum β-HCG pregnancy test result within 7 days prior to initiation of study treatment.

  13. Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results.

  14. Patient has known substance abuse or other psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results

  15. Patient is legally incapacitated or has limited legal capacity

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm A (Cemiplimab)

2 cycles of Cemiplimab (350 mg, i.v., Q3W) followed by sentinel lymph node biopsy

Patients will receive Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

Andre navne:
  • LIBTAYO
Placebo komparator: Arm B (placebo)

2 cycles of placebo followed by sentinel lymph node biopsy

Patients will receive NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Nodal micrometastases-free rate
Tidsramme: up to 36 months

rate of patients without nodal micrometastases after 2 cycles of treatment, determined by sentinel lymph node biopsy

up to 36 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Recurrence-free survival
Tidsramme: up to 66 months

time from randomization until date of the first of the following events: MCC recurrence, and MCC-related death

up to 66 months
Time to recurrence
Tidsramme: up to 66 months

defined as time from randomization until date of first MCC recurrence

up to 66 months
Overall survival
Tidsramme: up to 66 months

time from randomization until date of death from any cause

up to 66 months
Quality of life using FCRI-SF questionnaire
Tidsramme: up to 66 months

Quality of life determined using the FCRI-SF questionnaire

up to 66 months
Safety (AEs and SAEs)
Tidsramme: up to 66 months

incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5

up to 66 months
Disease specific survival
Tidsramme: up to 66 months

time from randomization until date of MCC-related death

up to 66 months
Quality of life using the mFACT-M questionnaire
Tidsramme: up to 66 months

Quality of life determined using the mFACT-M questionnaire

up to 66 months

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Investigation of prognostic and predictive biomarkers to estimate the risk of lymph node metastases and signs of immune activation in the sentinel lymph nodes
Tidsramme: up to 66 months

Biosamples will be used to determine the correlation of identified biomarkers with clinical outcome, i.e., nodal metastases-free rate, RFS, OS

up to 66 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Studieleder: Salah Al-Batran, Prof. Dr., Institut für Klinische Krebsforschung IKF GmbH
  • Ledende efterforsker: Ralf Gutzmer, Prof. Dr. med., Johannes Wesling Klinikum Minden
  • Ledende efterforsker: Juergen C. Becker, Prof. Dr. Dr., Translational Skin Cancer Research University Duisburg-Essen, Germany

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

29. maj 2026

Primær færdiggørelse (Anslået)

31. december 2029

Studieafslutning (Anslået)

31. juli 2031

Datoer for studieregistrering

Først indsendt

28. januar 2026

Først indsendt, der opfyldte QC-kriterier

28. januar 2026

Først opslået (Faktiske)

4. februar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • NeoMatryx

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .